This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedlaender, G. E.
Right arrow Articles by Baron, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedlaender, G. E.
Right arrow Articles by Baron, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

The Journal of Bone and Joint Surgery, Vol 66, Issue 4 602-607, Copyright © 1984 by Journal of Bone and Joint Surgery, Inc

JOURNAL CONTENTS

Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model

GE Friedlaender, RB Tross, AC Doganis, JM Kirkwood and R Baron

Wistar-Lewis rats received therapeutic doses of doxorubicin or methotrexate daily for five days, were pulse-labeled with a fluorescent compound (calcein) on the seventh and thirteenth days, and were killed fourteen days after initiation of the protocol. Proximal tail vertebrae were then evaluated histomorphometrically, and the effects of the chemotherapeutic agents on trabecular bone were quantitated with respect to changes in total bone mass, new-bone formation, and resorption. Short-term administration of methotrexate caused a 26.9 per cent reduction in net trabecular bone volume and doxorubicin, an 11.5 per cent decrease. Both drugs significantly and profoundly diminished bone-formation rates by nearly 60 per cent. The toxic effect on osteoblasts was also reflected in reduced volume and thickness of osteoid, but the total numbers of osteoblasts and the per cent of trabecular surface covered by bone-forming cells were not affected. The numbers of osteoclasts and the extent of their activity were not clearly different from those in untreated rats, but rates of resorption were not determined. The effects of chronic treatment with these chemotherapeutic agents on intact, fractured, and transplanted bone and the biomechanical significance of these changes has not yet been evaluated. Clinical Relevance: Chemotherapeutic agents have an adverse effect on normal physiological bone turnover, especially osteoblastic activity, and would also be expected to alter fracture-healing and bone-allograft incorporation by these same mechanisms. Knowledge of these changes and efforts to favorably affect the remodeling cycle must address these specific defects before bone allografts can be reliably used and fracture-healing can be improved concomitant with chemotherapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
R. TAMLER and S. EPSTEIN
Nonsteroid Immune Modulators and Bone Disease
Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 284 - 296.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
D. L. Muscolo, M. A. Ayerza, L. A. Aponte-Tinao, and M. Ranalletta
Use of Distal Femoral Osteoarticular Allografts in Limb Salvage Surgery
J. Bone Joint Surg. Am., November 1, 2005; 87(11): 2449 - 2455.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
Z. Chen, M. Maricic, T. L. Bassford, M. Pettinger, C. Ritenbaugh, A. M. Lopez, D. H. Barad, M. Gass, and M. S. LeBoff
Fracture Risk Among Breast Cancer Survivors: Results From the Women's Health Initiative Observational Study
Arch Intern Med, March 14, 2005; 165(5): 552 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. J. Elliot, S. J. Millward-Sadler, M. O. Wright, J. E. Robb, W. H. B. Wallace, and D. M. Salter
Effects of methotrexate on human bone cell responses to mechanical stimulation
Rheumatology, October 1, 2004; 43(10): 1226 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. H. Davies, B. A. J. Evans, M. E. M. Jenney, and J. W. Gregory
Effects of Chemotherapeutic Agents on the Function of Primary Human Osteoblast-Like Cells Derived from Children
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6088 - 6097.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Kawano, J. Taki, H. Tsuchiya, K. Tomita, and N. Tonami
Predicting the Outcome of Distraction Osteogenesis by 3-Phase Bone Scintigraphy
J. Nucl. Med., March 1, 2003; 44(3): 369 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M Wijnands and A Burgers
Stress fracture in long term methotrexate treatment for psoriatic arthritis
Ann Rheum Dis, August 1, 2001; 60(8): 736 - 739.
[Full Text] [PDF]

Home page
 JBJSHome page
W. F. Enneking and D. A. Campanacci
Retrieved Human Allografts : A Clinicopathological Study
J. Bone Joint Surg. Am., July 1, 2001; 83(7): 971 - 986.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
E. Croarkin
Osteopenia in the Patient With Cancer
Physical Therapy, February 1, 1999; 79(2): 196 - 201.
[Full Text]

Home page
 Endocr. Rev.Home page
S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel
The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Endocr. Rev., April 1, 1998; 19(2): 144 - 172.
[Abstract] [Full Text]